PERTH, Australia – After announcing its plans for an IPO on Nasdaq, Aussie biotech Immuron Ltd. said it is ramping up its phase II program for its immunotherapy IMM-124E in non-alcoholic steatohepatitis (NASH).
It expects results in Q4 at which point it will seek a partner.
Melbourne-based Immuron started enrolling pediatric patients in an NIH-sponsored phase II trial in NASH for IMM-124E. The study will evaluate whether 12 weeks of the treatment in children with confirmed NASH will decrease serum alanine transaminase (ALT).
IMM-124E is currently in an ongoing phase II study for the treatment of NASH. The NIH is also sponsoring two phase II studies in NASH as well as the pediatric NASH study. In phase I trials, the compound improved liver